Cargando…

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

BACKGROUND: Healthcare decision makers need to make trade-offs between different elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a framework that can help decision makers to understand stakeholders’ preferences and be explicit about the trade-offs that are being...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garau, Martina, Hampson, Grace, Devlin, Nancy, Mazzanti, Nicola Amedeo, Profico, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972119/ https://www.ncbi.nlm.nih.gov/pubmed/29623625 http://dx.doi.org/10.1007/s41669-017-0048-x

Ejemplares similares

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022)

A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
por: de Andrés-Nogales, Fernando, et al.
Publicado: (2021)

Development and pilot of a multicriteria decision analysis (MCDA) tool for health services administrators
por: Blythe, Robin, et al.
Publicado: (2019)

A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt
por: Elezbawy, Baher, et al.
Publicado: (2022)

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
por: Zinzani, P. L., et al.
Publicado: (2022)

Multicriteria decision analysis (MCDA) in health care: a systematic review of the main characteristics and methodological steps
por: Frazão, Talita D. C., et al.
Publicado: (2018)

Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)
por: Gasol, Montse, et al.
Publicado: (2022)

Non-Hodgkin Lymphoma (NHL) in Pakistan
por: Pervez, Shahid
Publicado: (2012)

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
por: Zozaya, Néboa, et al.
Publicado: (2022)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)
por: Vorobyev, V., et al.
Publicado: (2022)

Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut)
por: Guarga, Laura, et al.
Publicado: (2019)

Multicriteria mapping of stakeholder preferences in regulating nanotechnology
por: Hansen, Steffen Foss
Publicado: (2010)

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
por: Cheson, Bruce D., et al.
Publicado: (2016)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa
por: Miot, Jacqui, et al.
Publicado: (2012)

Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis
por: Xiang, Gao, et al.
Publicado: (2023)

Optimized landfill site selection for municipal solid waste by integrating GIS and multicriteria decision analysis (MCDA) technique, Hossana town, southern Ethiopia
por: Doboch Wanore, Tesfaye, et al.
Publicado: (2023)

Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab
por: Gaudêncio, Margarida, et al.
Publicado: (2021)

Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada
por: Tony, Michèle, et al.
Publicado: (2011)

Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient–Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context
por: Wagner, Monika, et al.
Publicado: (2018)

BCL-6 and other genomic alterations in non-Hodgkin's lymphoma (NHL).
por: Butler, M., et al.
Publicado: (1997)

Familial Aggregation of Non-Hodgkin's Lymphoma (NHL). A Case Report
por: Loves, Sandra SCM, et al.
Publicado: (2006)

Use of Rituximab in NHL Malt Type Pregnant in I° Trimester for Two Times
por: Sica, Antonello, et al.
Publicado: (2019)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Assessment of bone marrow infiltration in B-cell non-Hodgkin's lymphoma (NHL).
por: Dorey, E. L., et al.
Publicado: (1989)

Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs
por: Schey, C., et al.
Publicado: (2017)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Obinutuzumab/rituximab: Decreased platelet count and chronic COVID-19 pneumonia: case report
Publicado: (2020)

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
por: Edelmann, Jennifer, et al.
Publicado: (2021)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
por: Schieber, Timothy, et al.
Publicado: (2023)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL
por: Wang, H., et al.
Publicado: (2022)

Herbicide use in farming and other jobs in relation to non-Hodgkin’s lymphoma (NHL) risk
por: De Roos, Anneclaire J, et al.
Publicado: (2022)

Biomarkers in NHL
por: Malek, Sami N.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_obhif3bi1o3guvj0gf8rrcq9kn